Antibacterial and antibiofilm effects of flufenamic acid against methicillin-resistant Staphylococcus aureus

Area of Science:

• Microbiology
• Pharmacology
• Materials Science

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat as a surgical complication.
• Preventing MRSA infections is crucial in clinical settings.
• Flufenamic acid, an NSAID, is typically used for inflammation and pain.

Purpose of the Study:

• To investigate the antibacterial efficacy of flufenamic acid against MRSA.
• To elucidate the mechanisms behind flufenamic acid's antibacterial activity.
• To assess its potential for preventing MRSA infections and coating medical devices.

Main Methods:

• Minimal inhibitory concentration (MIC), time-kill, and resistance induction assays were performed.
• Antibiotic synergy tests evaluated combinations with oxacillin.
• Biofilm inhibition assays, RNA sequencing, and RT-PCR analyzed mechanisms.
• In vivo studies assessed efficacy in a mouse infection model.

Main Results:

• Flufenamic acid inhibited MRSA growth without inducing resistance at MIC.
• It demonstrated synergy with oxacillin and low mammalian cell toxicity.
• The drug prevented biofilm formation on implants and disrupted bacterial cell walls.
• Gene expression analysis revealed inhibition of peptidoglycan biosynthesis, quorum sensing, and biofilm pathways.
• Flufenamic acid successfully treated MRSA infections in mice.

Conclusions:

• Flufenamic acid exhibits potent antibacterial activity against MRSA.
• It offers a dual benefit of therapeutic potential and biofilm prevention on medical devices.
• Further development could lead to novel strategies against challenging MRSA infections.